Toni Choueiri: Poster 269 by our super star Eddy Saad at ASCO24

Toni Choueiri shared a post on X:

“Poster American Society of Clinical Oncology (ASCO24) 269 by our Dana-Farber Lank Center for Genitourinary Oncology super star Eddy Saad investigates Single nucleotide polymorphism (SNP) on Interleukin-7 (IL7) associated with Immune-related adverse events (irAEs) for Nivolumab (HR: 2.91, P=1.9e-03) versus Everolimus in Checkmate 025 trial (SNPxTRT P=0.003).

Also Merit Award recipient. Direct message if you have curated irAE data to replicate!”

Source: Toni Choueiri/X

Toni Choueiri is the Director of the Lank Center for Genitourinary (GU) Oncology at Dana-Farber Cancer Institute (DFCI), co-leader of the Kidney Cancer Program at Dana-Farber/Harvard Cancer Center, and the Jerome and Nancy Kohlberg Chair and Professor of Medicine at Harvard Medical School.

Dr. Choueiri is an elected member of the American Society of Clinical Investigation (ASCI). In addition, he is an Aresty Scholar from the Wharton School of Business at the University of Pennsylvania.